Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?

Clicks: 333
ID: 79602
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #7 of 7 articles by views in pharmacology & therapeutics

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Metabolic diseases have a tremendous impact on human morbidity and mortality. Numerous targets regulating adenosine monophosphate kinase (AMPK) have been identified for treating the metabolic syndrome (MetS), and many compounds are being used or developed to increase AMPK activity. In parallel, the cyclic nucleotide phosphodiesterase families (PDEs) have emerged as new therapeutic targets in cardiovascular diseases, as well as in non-resolved pathologies. Since some PDE subfamilies inactivate cAMP into 5'-AMP, while the beneficial effects in MetS are related to 5'-AMP-dependent activation of AMPK, an analysis of the various controversial relationships between PDEs and AMPK in MetS appears interesting. The present review will describe the various PDE families, AMPK and molecular mechanisms in the MetS and discuss the PDEs/PDE modulators related to the tissues involved, thus supporting the discovery of original molecules and the design of new therapeutic approaches in MetS.
Reference Key
lugnier2020cyclicpharmacology Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lugnier, Claire;Meyer, Alain;Talha, Samy;Geny, Bernard;
Journal pharmacology & therapeutics
Year 2020
DOI
S0163-7258(20)30003-6
URL
Keywords
cyclic nucleotide phosphodiesterase (pde) pde inhibitor adenosine monophosphate kinase (ampk) camp (cyclic amp) cgmp (cyclic gmp) metabolic syndrome (mets)

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.